Roth Capital upped their price objective on shares of Pozen (NASDAQ:POZN) from $8.00 to $9.00 in a research note issued on Wednesday, Analyst Ratings Net reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective indicates a potential upside of 33.14% from the stock’s previous close.
Separately, analysts at Zacks reiterated an “outperform” rating on shares of Pozen in a research note to investors on Thursday, September 5th. They now have a $9.00 price target on the stock.
Pozen (NASDAQ:POZN) traded up 1.20% on Wednesday, hitting $6.76. The stock had a trading volume of 676,726 shares. Pozen has a 1-year low of $4.26 and a 1-year high of $7.00. The stock has a 50-day moving average of $5.99 and a 200-day moving average of $5.5. The company’s market cap is $206.2 million.
Pozen (NASDAQ:POZN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.07. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.25 million. During the same quarter last year, the company posted ($0.19) earnings per share. Pozen’s revenue was up 188.9% compared to the same quarter last year. Analysts expect that Pozen will post $-0.53 EPS for the current fiscal year.
POZEN Inc (NASDAQ:POZN), is a pharmaceutical company focused on transforming medicine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.